source
- BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapyBridgeBio Pharma is preparing for a potential launch of its experimental drug BBP-418 aimed at treating limb-girdle muscular dystrophy type 2I/R9, pending FDA decision. The agency has set a review…
- AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidatesAbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company. The partnership covers two preclinical migraine programs and is valued at up to $75…